George R. Painter

Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA.

Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA.

Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA.

Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA.

Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA.

Emory Institute For Drug Development engages in drug discovery and development in industry and academia. It provides organization, facilities and resources to translate academic drug discovery into clinical candidates. The company was founded by Dennis C. Liotta in 2009 and is headquartered in Atlanta, GA.